Ticker	Market Cap	P/E Ratio	Revenue Growth	Net Margin	EPS	ROE	Debt/Equity	Dividend Yield	52W High	52W Low
TXG	9.32 B	-	-12.70%	-12.18%	-$0.59	-9.40%	0.10x	0.00%	$102.81	$12.34
TEM	11.98 B	-	21.60%	-17.77%	-$1.44	-67.44%	3.25x	0.00%	$93.38	$40.77
AVTR	11.69 B	-	0.50%	-8.81%	-$0.84	-9.70%	0.66x	0.00%	$17.45	$7.26
TECH	11.38 B	62.54x	1.30%	14.97%	$1.16	9.03%	0.14x	0.44%	$72.69	$43.07
RGEN	11.23 B	242.37x	11.90%	5.29%	$0.73	1.99%	0.33x	0.00%	$198.87	$100.99

Peer Valuation & Performance Analysis

Peer group analysis for 10x Genomics, Inc. (TXG) compared to its primary competitors (including TEM, AVTR, TECH) reveals distinct metrics. TXG trades at a valuation discount relative to its competitors, with a P/E ratio of -121.3x versus the peer average of 59.3x (representing a 304% discount). This discount might represent an undervalued entry opportunity or reflect specific risk factors the market is discounting. In terms of growth, TXG's revenue growth of -12.7% lags behind the peer average of 8.8%, indicating potential market share losses or slower industry adoption. Additionally, its net margin of -12.2% is below the peer average of -1.6%, suggesting higher operational costs or lower pricing power relative to peers.

Peer Performance Rankings

Ranking comparison across key performance metrics

P/E Ratio (Lower is Better)

🥇TECH↓

62.5x

🥈RGEN↓

242.4x

Revenue Growth

🥇TEM↑

+21.6%

🥈RGEN↑

+11.9%

🥉TECH↓

+1.3%

4thAVTR↓

+0.5%

5thTXG↓

-12.7%

Net Profit Margin

🥇TECH↑

15.0%

🥈RGEN↓

5.3%

🥉AVTR↓

-8.8%

4thTXG↓

-12.2%

5thTEM↓

-17.8%

Financial Rankings Summary

• TXG ranks #0 in P/E ratio, #5 in revenue growth, and #4 in profit margins

• Average ranking: #3 - 📊 Solid financials relative to peer group

• Rankings based on actual financial data from company reports

Historical Trading Data

Price and volume data with customizable timeframes

Timeframe:

Showing 15 of 15 trading sessions from the last 15 days

Date	Open	High	Low	Close	Volume	Daily Change
2026-10-23	$68.94	$71.83	$67.52	$71.55	2,227,263	+2.58%
2026-10-22	$73.85	$75.59	$67.25	$69.75	4,188,900	-7.73%
2026-10-21	$70.92	$77.55	$70.10	$75.59	3,122,100	+5.78%
2026-10-20	$69.52	$73.40	$67.53	$71.46	2,860,300	+2.25%
2026-10-19	$71.48	$72.48	$68.50	$69.89	2,526,800	+0.04%
2026-10-16	$71.91	$73.99	$67.52	$69.86	3,385,600	-3.49%
2026-10-15	$69.35	$73.74	$68.57	$72.39	4,315,700	-0.97%
2026-10-14	$69.52	$74.33	$68.45	$73.10	4,137,900	+1.82%
2026-10-13	$74.50	$74.55	$71.25	$71.79	4,040,100	-4.52%
2026-10-12	$79.18	$80.47	$71.61	$75.19	4,078,200	-6.77%
2026-10-09	$78.60	$85.12	$78.52	$80.65	3,685,000	+4.36%
2026-10-08	$73.50	$77.58	$70.94	$77.28	5,702,900	+1.55%
2026-10-07	$77.52	$82.72	$73.00	$76.10	9,373,600	-5.65%
2026-10-06	$100.33	$102.81	$79.90	$80.66	9,057,900	-17.47%
2026-10-05	$93.50	$98.32	$92.26	$97.74	3,097,400	+4.53%

Explore More Analysis for TXG

Additional research, tools, and technical breakdowns

Stock Analyzer Report

Deep-dive automated research and stock rating report.

DCF Fair Value Calculator

Discounted cash flow model and intrinsic value projection.

AI Price Predictions

Multi-scenario price predictions and consensus targets.

Insider Activity Tracker

Track buying/selling behavior of corporate insiders.

Earnings Calendar

Track upcoming and historical corporate earnings reports.

Market Insights & Research

Read the latest analysis articles and expert research.

10x Genomics, Inc.(TXG)Stock Performance & ReturnsNASDAQ

Returns, drawdowns and benchmark comparison

Peer Comparison